Information on Bedaquiline
If you have any question related to the Bedaquiline Donation Program (eligibility, process to access to the donation,... etc.), please address your inquiries to email@example.com
According to the WHO's Global TB Report 2014, an estimated 480 000 people developed multi-drug resistant TB (MDR-TB) in 2013 and 210,000 people died. Only one in four are diagnosed, and only one in five are put on treatment. Of these patients, less than half are successfully treated.
Left untreated, a person with MDR-TB may infect 10-15 people every year. Antibacterial resistance to anti-tuberculosis drugs is a major public health problem that arises as a result of improper prescribing or supply of antibiotics and/or problems for patients in adhering to a long, often toxic, therapy.
The world needs new solutions for treating MDR-TB patients. Bedaquiline, developed by Janssen Pharmaceuticals, is the first new class of antibiotics that has been FDA approved in over 50 years. The use of this drug in combination with existing drugs provides new hope for MDR-TB patients with very few treatment options.
For additional information on bedaquiline, please refer to the WHO information page: http://www.who.int/tb/challenges/mdr/bedaquilinefaqs/en/
For further information that can help countries introduce the new medicines: http://newtbdruginfo.org/
For more information on procurement of bedaquiline, or to request bedaquiline through the donation program, please refer to the information below.
In This Section
GDF is ISO 9001:2000 compliant for provision of quality-assured anti-TB drugs and related services to eligible national TB control programmes.